CLINICAL IMPACT
SANI detects deterioration earlier than any clinician or traditional monitor, across every indication. Below: the high-acuity indications the platform is designed for, ordered by clinical priority.
Sepsis detection hours before qsofa
SEPSIS: FEATURED USE CASE
The Objective: Surface the earliest sub-perceptual physiological signatures of sepsis, hours before they become detectable in standard vital signs, qSOFA, or MEWS. Give clinicians the lead time needed to initiate institutional sepsis bundles within the window where antibiotic timing meaningfully affects outcome.
The SANI Impact: Mortality rises 4–8% with every hour antibiotics are delayed after septic shock onset, yet manual screening depends on the cadence of intermittent vitals. SANI runs continuously in the background, generating risk-stratified alerts that complement existing screening workflows, including Epic Sepsis and Cerner sepsis pathways. Every alert is explainable at the sensor-signal level. No black-box scores.
RESPIRATORY SAFETY / OPIOID STEWARDSHIP
OIRD: Detected Before Desaturation
The Objective: Detect the prodromal signatures of opioid-induced respiratory depression hours before desaturation triggers a pulse-oximeter alarm. Standard spot-check vitals miss the non-linear physiological decline characteristic of opioid sedation, and continuous capnography is rarely deployed outside the ICU.
The SANI Impact: SANI provides high-acuity respiratory visibility on the general floor and in palliative-care settings, without contact, wearable compliance, or new charting burden. The platform monitors respiratory pattern continuously and generates real-time alerts, closing the gap between four-hour rounds and three-minute respiratory events. Failure-to-rescue events on the general floor are a top driver of preventable in-hospital mortality and high-stakes litigation.
Early CHF Decompensation Detection
HEART FAILURE & READMISSION REDUCTION
The Objective: Detect the earliest objective trends that precede CHF decompensation by days. Daily-weight protocols and subjective symptom reporting are lagging indicators. The window for medication titration closes before either of them registers a meaningful change.
The SANI Impact: CHF readmissions cost the U.S. system roughly $11B annually and trigger compounding HRRP penalties. SANI's continuous, ambient monitoring detects deterioration trends days before standard protocols, supporting early intervention across the acute-to-post-acute continuum: hospital, SNF, ALF, and home. Earlier detection in post-acute settings prevents the bounce-back ED visits that drive HRRP penalties for the discharging hospital.
ADDITIONAL PLATFORM CAPABILITIES
Beyond the Lead Indications
SANI's multi-modal sensor platform was engineered as a foundation, not a single-indication tool. The same explainable-alert framework supports COPD exacerbation monitoring, UTI signature detection, post-surgical monitoring, and mobility and gait stability — across the acute and post-acute continuum. Deployment scope of these capabilities is determined per facility based on clinical priorities.
Regulatory Notice: SANI is a Clinical Decision Support (CDS) platform. It is not intended to diagnose, cure, mitigate, treat, or prevent any disease. All clinical conclusions must be verified by a licensed healthcare professional. Performance figures referenced reflect internal validation and design-target ranges; prospective clinical validation is ongoing.